Mattias Mandorfer
Mattias Mandorfer is an expert in Hepatology at Medical University of Vienna (Austria). As of October 2026, ScienceLeadR ranks Mattias Mandorfer in the top 1% of experts worldwide for Hepatic Insufficiency, Liver Failure and Hypertension, Portal. Mattias Mandorfer has authored 779 publications, the most recent in 2026, and is an investigator in 16 clinical trials, 7 of them ongoing. SLR score: 3,271 (community average: 125). How the SLR is computed.
LeadR Profile
Hepatology
Subspecialties: Gastroenterology - Pharmacy
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2012 - 2026
Number : 779
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Blood- and Liver Stiffness-Based Non-Invasive Tests for Clinically Significant Portal Hypertension in Patients With cACLD and HCC. PMID 42928966 — research design, hypertension, blood, liver, hypertension, portal, prevalence, liver stiffness | Liver Int | 2026 | 0 |
| Circulating fibronectin levels are linked to liver function, matrix remodeling, and hemostatic complications in advanced chronic liver disease. PMID 42789231 — liver diseases, hemorrhage, hemostatics, portal vein, liver, fibronectins, thrombosis, veins, cholinesterases | Hepatol Int | 2026 | 0 |
| Austrian Society of Gastroenterology and Hepatology (ÖGGH) consensus on primary biliary cholangitis. PMID 42714609 — cholangitis, gastroenterology, antibodies, liver, diagnosis, therapeutics, peroxisome proliferator-activated receptors | Wien Klin Wochenschr | 2026 | 0 |
| Noninvasive test patterns across vascular and parenchymal liver diseases. PMID 42693274 — liver diseases, research design, hypertension, platelet count, portal vein, budd-chiari syndrome, liver, signs and symptoms, hypertension, portal, thrombosis, blood platelets, veins | Wien Klin Wochenschr | 2026 | 0 |
| Course of Portal Hypertension and Its Prognostic Impact After Liver Transplantation. PMID 42570327 — hypertension, liver transplantation, mortality, liver, hypertension, portal, transplants, gastrointestinal diseases, transplantation, thrombocytopenia | United European Gastroenterol J | 2026 | 0 |
Clinical Studies 16
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 2
Ongoing Clinical Trials
7 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| An Open Label Extension Study of Fazirsiran 2023-503497-21-00 — liver diseases, safety, alpha 1-antitrypsin deficiency, liver, therapeutics, alpha 1-antitrypsin | Phase 3 | Recruiting | 2023 |
| A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction Associated Steatotic Liver Disease (SYNERGY Outcomes) 2025-522674-36-00 — liver diseases, liver | Phase 3 | Recruiting | 2026 |
| TECA study 2024-513351-33-00 — liver diseases, hypertension, telmisartan, venous pressure, liver, hypertension, portal | Phase 2 | Recruiting | 2025 |
| A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction Associated Steatotic Liver Disease (SYNERGY Outcomes) NCT07165028 — liver diseases, non-alcoholic fatty liver disease, liver, alcoholics, incretins, fatty liver, fatty liver, alcoholic | Phase 3 | Recruiting | 2025 |
| A Study in Adults to Learn About Inherited Alpha 1 Antitrypsin Deficiency (AATD) and AATD Related Liver Problems NCT06512454 — liver diseases, lung, natural history, blood, alpha 1-antitrypsin deficiency, liver, history, alpha 1-antitrypsin | N/A | Recruiting | 2024 |
LeadR Networks
Main global connection map